Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and safety results expected for early 2021 –Lyon, France – September 10, 2020 –Osivax announced today that the Last Subject’s Last Visit (LSLV) occurred in the Phase 2a clinical trial of OVX836 universal Influenza …
Archives de la catégorie : 2020
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines — Company Secures EUR 17.5M from European Innovation Council and EUR 15.1M from Bpifrance as part of PSCP Covid-19 —Lyon, France – July 08, 2020 – Osivax announced today that it has received over EUR 30M in public funding from …
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Top line results expected by the first quarter of 2021 —Lyon, France – April 09, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focusing on the development of a universal influenza vaccine candidate, announced today that it completed …
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate — Phase 2a clinical trial on 300 healthy volunteers run under US IND —Lyon, France – January 21, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, enrolled the first participant in …